Supreet Agarwal

1.0k total citations
15 papers, 539 citations indexed

About

Supreet Agarwal is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Supreet Agarwal has authored 15 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Supreet Agarwal's work include Prostate Cancer Treatment and Research (8 papers), Cancer, Lipids, and Metabolism (4 papers) and Cancer Genomics and Diagnostics (3 papers). Supreet Agarwal is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Cancer, Lipids, and Metabolism (4 papers) and Cancer Genomics and Diagnostics (3 papers). Supreet Agarwal collaborates with scholars based in United States, China and Netherlands. Supreet Agarwal's co-authors include Michael L. Beshiri, Keith H. Jansson, Kathleen Kelly, Aian Neil Alilin, JuanJuan Yin, Qi Yang, Timothy C. Ryken, Zita A. Sibenaller, Mahfoud Assem and Mohammad A. Y. Alqudah and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Supreet Agarwal

13 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Supreet Agarwal United States 10 279 192 160 153 82 15 539
Alexis S. Lopez United States 6 226 0.8× 170 0.9× 98 0.6× 103 0.7× 86 1.0× 8 495
Xinghua Han China 15 349 1.3× 224 1.2× 168 1.1× 289 1.9× 66 0.8× 54 676
JuanJuan Yin United States 9 370 1.3× 258 1.3× 191 1.2× 215 1.4× 65 0.8× 11 648
Xuhong Fu China 12 488 1.7× 172 0.9× 87 0.5× 137 0.9× 77 0.9× 12 712
Shogo Okazaki Japan 15 451 1.6× 257 1.3× 167 1.0× 244 1.6× 50 0.6× 29 752
Allen Saliganan United States 12 263 0.9× 275 1.4× 202 1.3× 181 1.2× 74 0.9× 14 605
Fabiana Lüönd Switzerland 7 380 1.4× 330 1.7× 95 0.6× 237 1.5× 69 0.8× 9 683
Kateřina Bouchalová Czechia 12 193 0.7× 229 1.2× 62 0.4× 128 0.8× 41 0.5× 35 486
Daniel J. Smit Germany 13 286 1.0× 283 1.5× 72 0.5× 179 1.2× 85 1.0× 41 609
Ki-Chun Yoo South Korea 14 291 1.0× 199 1.0× 55 0.3× 153 1.0× 61 0.7× 20 536

Countries citing papers authored by Supreet Agarwal

Since Specialization
Citations

This map shows the geographic impact of Supreet Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Supreet Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Supreet Agarwal more than expected).

Fields of papers citing papers by Supreet Agarwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Supreet Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Supreet Agarwal. The network helps show where Supreet Agarwal may publish in the future.

Co-authorship network of co-authors of Supreet Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Supreet Agarwal. A scholar is included among the top collaborators of Supreet Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Supreet Agarwal. Supreet Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ahmad, Fahim, Kazutoshi Yamamoto, Daniel R. Crooks, et al.. (2025). Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer. Neoplasia. 70. 101235–101235.
2.
Beshiri, Michael L., Brian J. Capaldo, Ross Lake, et al.. (2024). Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer. Stem Cells. 42(6). 526–539. 3 indexed citations
3.
Beshiri, Michael L., Supreet Agarwal, Juan Juan Yin, & Kathleen Kelly. (2023). Prostate organoids: emerging experimental tools for translational research. Journal of Clinical Investigation. 133(10). 15 indexed citations
4.
Whitlock, Nichelle C., Brian J. Capaldo, Anson T. Ku, et al.. (2022). Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A. Discover Oncology. 13(1). 97–97. 4 indexed citations
5.
Adelaiye‐Ogala, Remi, Berkley E. Gryder, Yen Thi Minh Nguyen, et al.. (2020). Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. Molecular Cancer Therapeutics. 19(7). 1436–1447. 34 indexed citations
6.
Li, Lechen, Amir H. Ameri, Simeng Wang, et al.. (2019). EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 38(35). 6241–6255. 106 indexed citations
7.
Beshiri, Michael L., Caitlin M. Tice, Crystal Tran, et al.. (2018). A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clinical Cancer Research. 24(17). 4332–4345. 145 indexed citations
8.
Pan, Hong, Keith H. Jansson, Michael L. Beshiri, et al.. (2017). Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget. 8(44). 77181–77194. 35 indexed citations
9.
10.
Agarwal, Supreet, Paul G. Hynes, Heather Tillman, et al.. (2015). Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Reports. 13(10). 2147–2158. 44 indexed citations
11.
12.
Alqudah, Mohammad A. Y., et al.. (2013). NOTCH3 Is a Prognostic Factor That Promotes Glioma Cell Proliferation, Migration and Invasion via Activation of CCND1 and EGFR. PLoS ONE. 8(10). e77299–e77299. 45 indexed citations
13.
Agarwal, Supreet, et al.. (2013). Abstract 2194: Tyrosyl DNA phosphodiesterase I is a prognostic factor and its inhibition synergizes response to topoisomerase poisons in malignant glioma.. Cancer Research. 73(8_Supplement). 2194–2194. 1 indexed citations
14.
Assem, Mahfoud, et al.. (2012). Enhancing Diagnosis, Prognosis, and Therapeutic Outcome Prediction of Gliomas Using Genomics. OMICS A Journal of Integrative Biology. 16(3). 113–122. 22 indexed citations
15.
Agarwal, Supreet, et al.. (1985). Heavy chain variable region. Multiple gene segments encode anti-4-(hydroxy-3-nitro-phenyl)acetyl idiotypic antibodies.. The Journal of Experimental Medicine. 161(6). 1272–1292. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexis S. Lopez Breakdown of academic impact, for papers by Xinghua Han Breakdown of academic impact, for papers by JuanJuan Yin Breakdown of academic impact, for papers by Xuhong Fu Breakdown of academic impact, for papers by Shogo Okazaki Breakdown of academic impact, for papers by Allen Saliganan Breakdown of academic impact, for papers by Fabiana Lüönd Breakdown of academic impact, for papers by Kateřina Bouchalová Breakdown of academic impact, for papers by Daniel J. Smit Breakdown of academic impact, for papers by Ki-Chun Yoo
Rankless by CCL
2026